Promoted Content

Promoted Content

All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Shanghai SIMR Biotechnology

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

CPhI India 2021

Participation Not Confirmed

Update your events

Shanghai SIMR Biotechnology's First Patient Successfully Dosed with the Candidate Drug SR419 for Peripheral Neuropathic Pain

Contact the Supplier

Lead Product(s): SR419

Therapeutic Area: Neurology Product Name: SR419

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 20, 2020

Details:

The current clinical trial is the first study for SR419 in the patient population, purposing to explore the efficacy, safety, tolerability and pharmacokinetics of SR419 in patients with neuropathic pain.